A Phase 2 Study of Seviteronel (INO-464) in Patients with Metastatic Castration-Resistant Prostate Cancer Post-Enzalutamide Treatment

BACKGROUND: Seviteronel was being developed by Innocrin Pharamceuticals as a selective cytochrome P450c17a (CYP17) 17,20-lyase (lyase) inhibitor and androgen receptor (AR) antagonist with activity against prostate cancer cells in vitro and in vivo. This open-label Phase II clinical study evaluated t...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Genitourin Cancer
Egile Nagusiak: Madan, Ravi A., Schmidt, Keith T., Karzai, Fatima, Peer, Cody J., Cordes, Lisa M., Chau, Cindy H., Steinberg, Seth M., Owens, Helen, Eisner, Joel, Moore, William R., Dahut, William L., Gulley, James L., Figg, William D.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7415516/
https://ncbi.nlm.nih.gov/pubmed/32327394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2019.11.002
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak